Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy MRNA?
Source: Benzinga
- Revenue Forecast Increase: At the 44th Annual J.P. Morgan Healthcare Conference, Moderna announced an expected revenue of approximately $1.9 billion for 2025, which is $100 million above the previously communicated midpoint, enhancing investor confidence and driving stock price up.
- Operating Expense Improvement: The company also lowered its projected GAAP operating expenses for 2025 by $200 million, demonstrating improved cost control capabilities that lay a solid foundation for future profitability.
- Increased Cash Balance: Moderna anticipates an end-of-year cash balance of approximately $8.1 billion, providing strong support for the company's R&D and market expansion efforts, further solidifying its market position.
- Strong Stock Performance: Following the positive news, Moderna's stock surged 12.8% to $38.20 on Tuesday, reflecting market optimism regarding its future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 52.845
Low
17.00
Averages
32.47
High
63.00
Current: 52.845
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Crude Oil Prices Surge Amid Ongoing Middle East Conflict
- Oil Price Surge: Amid the ongoing U.S.-Israel-Iran conflict, April WTI crude futures rose by 1.05% to $75.34 per barrel, reflecting market concerns over energy supply disruptions.
- Market Response: Despite the tensions in the Middle East, S&P futures increased by 0.13%, Dow futures edged up by 0.03%, and Nasdaq futures rose by 0.22%, indicating a recovery in investor confidence.
- Trump's Statement: President Trump announced that the U.S. will ensure the free flow of energy globally and may deploy the Navy to escort tankers through the Strait of Hormuz, aiming to alleviate concerns over potential supply interruptions.
- Bitcoin Impact: Bitcoin surged nearly 7% in the past 24 hours, boosting stocks like Strategy, Robinhood, and Coinbase in pre-market trading, highlighting the active state of the cryptocurrency market.
See More
Movers: Moderna, CrowdStrike, GitLab, Coinbase, Strategy, Broadcom, and Others
- Stock Market Movement: Stock futures were showing slight increases on Wednesday.
- Investor Sentiment: Investors are assessing the potential for the U.S.-Iran conflict to escalate into a prolonged war.
See More
Moderna Shares Surge as Major Risk is Removed.
- Moderna's Stock Performance: Moderna's stock experienced a rally on Wednesday following positive news regarding a legal settlement.
- Patent Litigation Resolution: The company settled patent litigation with Arbutus Biopharma and Genevant Sciences, which contributed to the stock's increase.
See More
U.S. Stocks Decline Amid Rising Iran Conflict Tensions
- CrowdStrike Earnings Beat: CrowdStrike Holdings Inc. reported fourth-quarter revenue of $1.31 billion, exceeding estimates, with subscription revenue up 23% year-over-year and annual recurring revenue hitting $5.25 billion, highlighting massive growth opportunities from AI adoption, as the stock rose 1.70% to $391.42.
- Mobix Labs Stock Surge: Mobix Labs, Inc. shares skyrocketed 532.77% to $1.12 after securing a production purchase order for high-reliability filtering components essential to the U.S. Navy’s Tomahawk missile program, underscoring rising demand from ongoing missile manufacturing schedules, with the stock gaining an additional 5.36% in after-hours trading.
- Micron Stock Decline: Micron Technology Inc. saw its stock drop 7.99% to $379.68, despite a 52-week high of $455.48, reflecting growing concerns about future performance amid semiconductor industry volatility.
- Target Exceeds Profit Expectations: Target Corporation's stock advanced 6.77% to $120.80, with adjusted earnings of $2.44 per share despite a slight sales dip, driven by growth in food, beauty, and toy categories, while gross margins improved to 26.6% through lower costs and advertising gains.
See More
Moderna Settles Patent Litigation with Arbutus and Genevant
- Settlement Amount Confirmed: Moderna has settled patent litigation with Arbutus Biopharma and Genevant Sciences by agreeing to pay $950 million related to its Spikevax and mRESVIA vaccines, ensuring no future royalties are owed, thereby alleviating financial burdens on the company.
- Cash Flow Outlook Upgraded: With the settlement fee to be incurred in Q3, Moderna now expects cash and cash equivalents to reach between $4.5 billion and $5 billion by year-end, indicating robust financial health and future investment capacity.
- Potential Liability Risks: Despite the settlement, Moderna could still face an additional $1.3 billion in liabilities depending on the outcome of its appeal to the US Federal Circuit, which may impact the company's cash flow and financial planning.
- Vaccine Portfolio Prospects: The settlement provides certainty for Moderna's entire infectious disease portfolio, including future vaccines like mNEXSPIKE and mCOMBRIAX, enhancing the company's competitive edge and innovation capabilities in the vaccine market.
See More
Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant
- Settlement Agreement: Moderna has reached a settlement of up to $2.25 billion with Arbutus and Genevant, resolving all enforcement actions related to its COVID-19 vaccine Spikevax and RSV vaccine mRESVIA, ensuring no future royalties and enhancing strategic stability in its infectious disease portfolio.
- Significant Financial Impact: Under the agreement, Moderna will pay $950 million in Q3 2026, with the remaining $1.3 billion contingent on further litigation outcomes, which could significantly affect future cash flows depending on the litigation results.
- Positive Market Reaction: Following the settlement announcement, Moderna's shares surged 11% in after-hours trading, indicating investor optimism about the company's future, while Arbutus shares fell 8%, reflecting market uncertainty regarding its prospects.
- Optimistic Liquidity Outlook: Moderna expects to have $5.4 to $5.9 billion in liquidity by the end of 2026, demonstrating that after resolving legacy issues, the company can focus on future vaccine development and market opportunities, further solidifying its leadership in the biopharmaceutical industry.
See More
Crude Oil Prices Surge Amid Ongoing Middle East Conflict
- Oil Price Surge: Amid the ongoing U.S.-Israel-Iran conflict, April WTI crude futures rose by 1.05% to $75.34 per barrel, reflecting market concerns over energy supply disruptions.
- Market Response: Despite the tensions in the Middle East, S&P futures increased by 0.13%, Dow futures edged up by 0.03%, and Nasdaq futures rose by 0.22%, indicating a recovery in investor confidence.
- Trump's Statement: President Trump announced that the U.S. will ensure the free flow of energy globally and may deploy the Navy to escort tankers through the Strait of Hormuz, aiming to alleviate concerns over potential supply interruptions.
- Bitcoin Impact: Bitcoin surged nearly 7% in the past 24 hours, boosting stocks like Strategy, Robinhood, and Coinbase in pre-market trading, highlighting the active state of the cryptocurrency market.
See More
Movers: Moderna, CrowdStrike, GitLab, Coinbase, Strategy, Broadcom, and Others
- Stock Market Movement: Stock futures were showing slight increases on Wednesday.
- Investor Sentiment: Investors are assessing the potential for the U.S.-Iran conflict to escalate into a prolonged war.
See More
Moderna Shares Surge as Major Risk is Removed.
- Moderna's Stock Performance: Moderna's stock experienced a rally on Wednesday following positive news regarding a legal settlement.
- Patent Litigation Resolution: The company settled patent litigation with Arbutus Biopharma and Genevant Sciences, which contributed to the stock's increase.
See More
U.S. Stocks Decline Amid Rising Iran Conflict Tensions
- CrowdStrike Earnings Beat: CrowdStrike Holdings Inc. reported fourth-quarter revenue of $1.31 billion, exceeding estimates, with subscription revenue up 23% year-over-year and annual recurring revenue hitting $5.25 billion, highlighting massive growth opportunities from AI adoption, as the stock rose 1.70% to $391.42.
- Mobix Labs Stock Surge: Mobix Labs, Inc. shares skyrocketed 532.77% to $1.12 after securing a production purchase order for high-reliability filtering components essential to the U.S. Navy’s Tomahawk missile program, underscoring rising demand from ongoing missile manufacturing schedules, with the stock gaining an additional 5.36% in after-hours trading.
- Micron Stock Decline: Micron Technology Inc. saw its stock drop 7.99% to $379.68, despite a 52-week high of $455.48, reflecting growing concerns about future performance amid semiconductor industry volatility.
- Target Exceeds Profit Expectations: Target Corporation's stock advanced 6.77% to $120.80, with adjusted earnings of $2.44 per share despite a slight sales dip, driven by growth in food, beauty, and toy categories, while gross margins improved to 26.6% through lower costs and advertising gains.
See More
Moderna Settles Patent Litigation with Arbutus and Genevant
- Settlement Amount Confirmed: Moderna has settled patent litigation with Arbutus Biopharma and Genevant Sciences by agreeing to pay $950 million related to its Spikevax and mRESVIA vaccines, ensuring no future royalties are owed, thereby alleviating financial burdens on the company.
- Cash Flow Outlook Upgraded: With the settlement fee to be incurred in Q3, Moderna now expects cash and cash equivalents to reach between $4.5 billion and $5 billion by year-end, indicating robust financial health and future investment capacity.
- Potential Liability Risks: Despite the settlement, Moderna could still face an additional $1.3 billion in liabilities depending on the outcome of its appeal to the US Federal Circuit, which may impact the company's cash flow and financial planning.
- Vaccine Portfolio Prospects: The settlement provides certainty for Moderna's entire infectious disease portfolio, including future vaccines like mNEXSPIKE and mCOMBRIAX, enhancing the company's competitive edge and innovation capabilities in the vaccine market.
See More
Moderna Settles for Up to $2.25 Billion with Arbutus and Genevant
- Settlement Agreement: Moderna has reached a settlement of up to $2.25 billion with Arbutus and Genevant, resolving all enforcement actions related to its COVID-19 vaccine Spikevax and RSV vaccine mRESVIA, ensuring no future royalties and enhancing strategic stability in its infectious disease portfolio.
- Significant Financial Impact: Under the agreement, Moderna will pay $950 million in Q3 2026, with the remaining $1.3 billion contingent on further litigation outcomes, which could significantly affect future cash flows depending on the litigation results.
- Positive Market Reaction: Following the settlement announcement, Moderna's shares surged 11% in after-hours trading, indicating investor optimism about the company's future, while Arbutus shares fell 8%, reflecting market uncertainty regarding its prospects.
- Optimistic Liquidity Outlook: Moderna expects to have $5.4 to $5.9 billion in liquidity by the end of 2026, demonstrating that after resolving legacy issues, the company can focus on future vaccine development and market opportunities, further solidifying its leadership in the biopharmaceutical industry.
See More
